This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Update (4:25 p.m.): Updated with Tuesday market close information.
NEW YORK (TheStreet) -- Inovio Pharmaceuticals (INO - Get Report) surged Tuesday morning after the company started an immune therapy trial for head and neck cancer caused by HPV.
But the stock plunged in the afternoon after TheStreet's Adam Feuerstein wrote CEO Joseph Kim is trying to curb expectations for the soon-to-be-announced results from its phase II study of its DNA vaccine VGX-3100 in women with cervical pre-cancerous lesions.
The stock closed down 13.36%, or $1.44, to $9.34. More than 11.3 million shares changed hands, which surpassed the average volume of 1,521,180.